Ignite Creation Date:
2024-05-05 @ 10:17 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01074398
Status:
UNKNOWN
Last Update Posted:
2010-02-24
First Post:
2010-02-23
Brief Title:
Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
Sponsor:
Gynecologic Oncology Group
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
ERCC1 Expression as a Predictor of Progression Free and Overall Survival in Patients With Epithelial Ovarian Cancer Treated on GOG Protocols 0172 and 0182
Status:
UNKNOWN
Status Verified Date:
2010-02
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer It may also help doctors predict how well patients will respond to treatment
PURPOSE This research study is looking at biomarkers in predicting response in patients with advanced ovarian epithelial cancer fallopian tube cancer or primary peritoneal cancer
PURPOSE This research study is looking at biomarkers in predicting response in patients with advanced ovarian epithelial cancer fallopian tube cancer or primary peritoneal cancer
Detailed Description:
OBJECTIVES
Primary
To evaluate ERCC1 tumor expression as measured by IHC as a predictor of progression-free and overall survival of patients with advanced ovarian epithelial cancer
Secondary
To correlate ERCC1 single-nucleotide polymorphisms C8092A and codon 118 with ERCC1 tumor expression
OUTLINE This is a multicenter study
Blood and paraffin-embedded tumor tissue samples are analyzed for ERCC1 tumor expression by IHC and single-nucleotide polymorphisms
Primary
To evaluate ERCC1 tumor expression as measured by IHC as a predictor of progression-free and overall survival of patients with advanced ovarian epithelial cancer
Secondary
To correlate ERCC1 single-nucleotide polymorphisms C8092A and codon 118 with ERCC1 tumor expression
OUTLINE This is a multicenter study
Blood and paraffin-embedded tumor tissue samples are analyzed for ERCC1 tumor expression by IHC and single-nucleotide polymorphisms
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GOG-8012 | None | None | None |